Japan's Daiichi Sankyo has claimed its first worldwide approval for Ezharmia, a first-in-class dual EZH1 and EZH2 inhibitor for the treatment of patients with relapsed or refractory adult T-cell ...
Daiichi Sankyo has a second approval in Japan for Ezharmia, its first-in-class dual EZH1 and EZH2 inhibitor, as a treatment for relapsed or refractory peripheral T-cell lymphoma (PTCL).
Hosted on MSN12mon
Novartis (NVS) to Undertake Job Cuts in Development DepartmentThe candidate is an early-stage investigational dual inhibitor of enhancer of zeste homolog 1 and 2 (EZH1 and EZH2) proteins currently being tested in patients with solid tumors or lymphomas.
The acquisition added pelabresib (late-stage BET inhibitor for myelofibrosis) and tulmimetostat (early-stage dual EZH2 and EZH1 inhibitor for solid tumors or lymphomas) to NVS’ pipeline.
Using an unbiased approach, this important study discovered a role of Ezh2 in the differentiation of granule neuron precursors, the cell of origin for Shh group of medulloblastoma. Furthermore, the ...
The critical role of EZH2, an essential epigenetic regulator, in cancer progression and treatment is underscored in this new review article published in Genes & Diseases. The study highlights the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback